Langenfeld, Germany (PRWEB) July 12, 2006
Labtec has started phase I trials for Sufentanil TDS in early July. The study is designed to characterize the pharmacokinetic profile of the system. Furthermore pharmacodynamic as well as safety parameters will be determined.
The patch is not only very small but at the same time has an unusually low drug content. This is made possible by the adhesive blend which is releasing the drug with unparalleled efficiency. High patient comfort is achieved by use of a non-woven backing. Unlike most backing films used in transdermal systems, the material is non-occlusive and allows the skin to breathe and maintain its integrity throughout the application period of one week.
“After the huge success of our Fentanyl patch, which is marketed by our licensee ratiopharm and several other leading generic companies in Europe, we are looking forward to seeing the first clinical data of Sufentanil TDS®, soon. In our opinion this is the logical next generation product for severe chronic pain. Sufentanil is one of the most potent drug in its class, seven times more potent than fentanyl and at the same time offers various advantages in terms of safety and efficacy for chronic pain treatment with a transdermal system,” says Labtec´s founder Dr. Günter Cordes.
Labtec GmbH is a leading drug delivery company specialised on development of matrix-type transdermal and topical patches as well as fast dissolving oral films (Rapidfilms).
Dr. Ingo Lehrke; Business Development & Licensing
Labtec GmbH | http://www.labtec-pharma.com | Raiffeisenstrasse 3a | D-40764 Langenfeld | Germany
T: +49 2173 9735-0